Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Jeremy M. Deutsch"'
Publikováno v:
F1000Research, Vol 9 (2020)
The SMARCB1/INI1 gene was first discovered in the mid-1990s, and since then it has been revealed that loss of function mutations in this gene result in aggressive rhabdoid tumors. Recently, the term “rhabdoid tumor” has become synonymous with dec
Externí odkaz:
https://doaj.org/article/aa2cbd9fdf9f40eb8d1425fc09ac5f86
Autor:
Nathaniel A. Parker, Yasmine Hussein Agha, Charles Scott Buess, Daniel Lalich, Jeremy M. Deutsch
Publikováno v:
F1000Research, Vol 9 (2020)
Primary rectal squamous cell carcinoma is rare compared to adenocarcinoma, which is the predominant histologic type most commonly discovered at the time of colorectal carcinoma diagnosis. Due to the infrequent nature of this malignancy, data on tumor
Externí odkaz:
https://doaj.org/article/ed62fde8869a492f902a56b03c709462
Autor:
Khalil Choucair, Seth J. Page, Bassam I. Mattar, Christopher S. Dakhil, Nassim H. Nabbout, Jeremy M. Deutsch, Quoc V. Truong, Phu V. Truong, Dennis F. Moore, Michael W. Cannon, K. James Kallail, Joseph A. Moore, Shaker R. Dakhil, Radwan Diab, Syed Kamran, Pavan S. Reddy
Publikováno v:
Clinical breast cancer.
RNA-based genomic risk assessment estimates chemotherapy benefit in patients with hormone-receptor positive (HR+)/Human Epidermal Growth Factor 2-negative (ERBB2-) breast cancer (BC). It is virtually used in all patients with early HR+/ERBB2- BC rega
Publikováno v:
F1000Research
The SMARCB1/INI1 gene was first discovered in the mid-1990s, and since then it has been revealed that loss of function mutations in this gene result in aggressive rhabdoid tumors. Recently, the term “rhabdoid tumor” has become synonymous with dec
Publikováno v:
Cureus
Malignant SMARCB1/INI1-deficient extrarenal rhabdoid tumors are aggressive tumors that are extremely rare in adults. A 56-year-old male presented with the chief complaints of unilateral lower abdominal and pelvic pain. He underwent urgent surgical in
Autor:
Jeremy M Deutsch, Yasmine Hussein Agha, Daniel Lalich, Charles Scott Buess, Nathaniel A Parker
Publikováno v:
F1000Research
Primary rectal squamous cell carcinoma is rare compared to adenocarcinoma, which is the predominant histologic type most commonly discovered at the time of colorectal carcinoma diagnosis. Due to the infrequent nature of this malignancy, data on tumor
Publikováno v:
Cureus
Inhibitors of cytotoxic T-lymphocyte-associated antigen-4, programmed cell death protein-1, and programmed death-ligand 1 have been shown to produce significant antitumor activity in multiple malignancies, and have become essential oncology standard-
Autor:
Seth Joel Page, Eric A. Carlson, Quoc Truong, Michael W. Cannon, Shaker R. Dakhil, Jeremy M Deutsch, Phu Van Truong, Christopher Dakhil, Travis Lee Koeneke, K James Kallail, Pavan S. Reddy, Bassam I. Mattar, Khalil Choucair, Dennis F. Moore, Nassim H. Nabbout
Publikováno v:
Journal of Clinical Oncology. 39:3027-3027
3027 Background: Liquid biopsy is a promising, rapid and minimally invasive genetic test examining circulating tumor DNA. It offers a significant potential in selecting signal-matched therapeutic options. Methods: A retrospective chart review was con
Autor:
Christopher Dakhil, Quoc Truong, Pavan S. Reddy, Khalil Choucair, Dennis F. Moore, Jeremy M Deutsch, Eric A. Carlson, Travis Lee Koeneke, K James Kallail, Shaker R. Dakhil, Michael W. Cannon, Nassim H. Nabbout, Seth Joel Page, Phu Van Truong, Bassam I. Mattar
Publikováno v:
Journal of Clinical Oncology. 38:3527-3527
3527 Background: Liquid biopsy is a promising and minimally invasive genetic test examining plasma circulating tumor DNA. Coupled with the rapidly developing next-generation sequencing (NGS) technologies, it holds the potential for implementation in
Autor:
Bassam I. Mattar, Seth Joel Page, Pavan S. Reddy, Phu Van Truong, Jeremy M Deutsch, Chris Dakhil, Derek Young, Nassim H. Nabbout, Michael W. Cannon, Shaker R. Dakhil, Patricia Bluml, Quoc Truong
Publikováno v:
Journal of Clinical Oncology. 36:e19505-e19505
e19505Background: Filgrastim-sndz was the first biosimilar granulocyte colony stimulating factor to be approved by the FDA for the same indications, including peripheral blood stem cell mobilizatio...